Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2016

View Archived Issues

mAbxience and UCAB to lead palivizumab biosimilar project for RSV

Umecrine Cognition raises funds to support clinical development of GR-3027

ANI to acquire Inderal LA assets from Cranford Pharmaceuticals

FDA grants orphan drug designation for PNT-2258 for the treatment of DLBCL

Sylentis reports positive phase II results for SYL-1001

DREAM silencing associated with early neuroprotection in Huntington's disease

Ritter Pharmaceuticals initiates phase IIb/III study of RP-G28

First patients dosed in Quark Pharmaceuticals' pivotal studies

Inovio Pharmaceuticals acquires Bioject's needle-free injection technology

Tesaro submits NDA for intravenous rolapitant

Imbruvica available in U.S. as first-line treatment for CLL

Japanese scientists patent E-NPP 2 inhibitors

UCL Business discloses cyclophilin D inhibitors

ViveBio and Butantan Institute collaborate to evaluate ViveST technology in dengue trial

Northwestern University reports development of APOBEC-3G expression enhancers

Taisho Pharmaceutical presents antibacterial agents

FDA accepts Aeglea's IND for AEB-1102 for hematological malignancies

Eli Lilly develops novel EP4 receptor antagonists

Celator's phase III trial of Vyxeos for high-risk AML meets primary endpoint

Epidiolex treatment leads to significant reduction in convulsive seizures in phase III pivotal trial

FDA grants priority review to atezolizumab BLA for advanced bladder cancer

Navidea Biopharmaceuticals and Platinum sign agreement reaffirming loan obligations

miR-26b may be useful as a prognostic biomarker in advanced breast cancer

BioInvent and Oncurious partner with research consortium for phase I/IIa study of TB-403

Takeda and Frazier Healthcare launch Outpost Medicine

Lower TSPO expression may be a marker of poor prognosis in ACC

Dacomitinib evaluated in advanced or metastatic PSCC chemonaive patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...